Fourteen-Year Temporal Trends in Patients Hospitalized for Mitral Regurgitation: The Increasing Burden of Mitral Valve Prolapse in Men

Mitral regurgitation (MR) is the second most common valvular heart disease in Europe. The aging of the population and the increase in post-infarction survival could increase the prevalence of MR. To estimate the burden of patients hospitalized for MR in France in 2019 and temporal trends by etiology and sex from 2006 to 2020, we selected all patients hospitalized for MR using the national hospital database. In 2019, 49.2% of such patients had mitral valve prolapse (MVP), 17.1% had ischemic MR, 9.9% had rheumatic MR and 4.4% had MR with cardiomyopathy. The mean age of MVP patients was 67.8 years, and 34% were women. Among 89% of MVP inpatients who had received mitral valve repair or replacement, 55% received surgical repair, 13% received percutaneous repair and 25% received replacement. The all-cause mortality of one year after a mitral procedure of MVP was 5.4%. Among ischemic MR inpatients, 29% have had a mitral valve replacement, 16% a surgical repair and 19% a percutaneous repair. Between 2006 and 2019, the age-standardized rates of patients hospitalized for MVP have increased by 60%, especially in men (+80%) with 5.3/100,000 Person-Years (PY). The age-standardized rates of patients hospitalized for ischemic MR have increased by 25% with 1.8/100,000 PY; that of rheumatic MR has decreased by 36%. The study found that the burden of MVP in hospitals has increased substantially, especially among men. These results emphasize the need to monitor these temporal trends and anticipate care needs in the coming years.

[1]  S. Woolf,et al.  Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021. , 2021, JAMA.

[2]  A. Banerjee,et al.  Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality , 2020, European heart journal. Quality of care & clinical outcomes.

[3]  J. Chambers,et al.  Outpatient management of heart valve disease following the COVID-19 pandemic: implications for present and future care , 2020, Heart.

[4]  M. Enriquez-Sarano,et al.  Presentation and outcomes of mitral valve surgery in France in the recent era: a nationwide perspective , 2020, Open Heart.

[5]  M. Enriquez-Sarano,et al.  Dismal Outcomes and High Societal Burden of Mitral Valve Regurgitation in France in the Recent Era: A Nationwide Perspective , 2020, Journal of the American Heart Association.

[6]  M. Landray,et al.  COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England , 2020, The Lancet.

[7]  Roy T Sabo,et al.  Excess Deaths From COVID-19 and Other Causes, March-April 2020. , 2020, JAMA.

[8]  L. Pantoni,et al.  Stroke care during the COVID‐19 pandemic: experience from three large European countries , 2020, European journal of neurology.

[9]  Brian C. Case,et al.  Guidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic , 2020, Cardiovascular Revascularization Medicine.

[10]  T. H. Nguyen,et al.  Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017 , 2020, Circulation.

[11]  Jeroen J. Bax,et al.  Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. , 2019, Circulation.

[12]  Jeroen J. Bax,et al.  MITRA-FR vs. COAPT: lessons from two trials with diametrically opposed results , 2019, European heart journal cardiovascular Imaging.

[13]  R. Bonow,et al.  Is mitral valve disease treated differently in men and women? , 2019, European journal of preventive cardiology.

[14]  A. Sannino,et al.  Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. , 2019, JACC. Cardiovascular imaging.

[15]  P. Voisine,et al.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.

[16]  M. Wood,et al.  Valvular Heart Disease and Heart Failure in Women. , 2019, Heart failure clinics.

[17]  Y. Juillière Lessons from MITRA-FR and COAPT studies: Can we hope for an indication for severe functional mitral regurgitation in systolic heart failure? , 2019, Archives of cardiovascular diseases.

[18]  D. Maucort-Boulch,et al.  Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation , 2018, The New England journal of medicine.

[19]  B. Zhang,et al.  Repair or replacement for severe ischemic mitral regurgitation , 2018, Medicine.

[20]  Mikhail A. Dziadzko,et al.  Outcome and undertreatment of mitral regurgitation: a community cohort study , 2018, The Lancet.

[21]  J. Ferrières,et al.  Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015 , 2017, Circulation.

[22]  J. Coste,et al.  Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. , 2017, Revue d'epidemiologie et de sante publique.

[23]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[24]  Andrea Beaton,et al.  Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015 , 2017, The New England journal of medicine.

[25]  N. Danchin,et al.  Acute coronary syndrome in women: rising hospitalizations in middle-aged French women, 2004–14 , 2017, European heart journal.

[26]  C. Di Mario,et al.  Immediate and 12-Month Outcomes of Ischemic Versus Nonischemic Functional Mitral Regurgitation in Patients Treated With MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology). , 2017, The American journal of cardiology.

[27]  Emilia Bagiella,et al.  Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. , 2016, The New England journal of medicine.

[28]  M. Enriquez-Sarano,et al.  Comprehensive Imaging in Women With Organic Mitral Regurgitation: Implications for Clinical Outcome. , 2016, JACC. Cardiovascular imaging.

[29]  M. Mack,et al.  Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. , 2015, Journal of the American College of Cardiology.

[30]  M. Lapeyre-Mestre,et al.  French health insurance databases: What interest for medical research? , 2015, La Revue de medecine interne.

[31]  Veikko Salomaa,et al.  Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations , 2015, Heart.

[32]  V. Roger,et al.  The changing epidemiology of myocardial infarction in Olmsted County, Minnesota, 1995-2012. , 2015, The American journal of medicine.

[33]  Alec Vahanian,et al.  Epidemiology of acquired valvular heart disease. , 2014, The Canadian journal of cardiology.

[34]  Timothy J Gardner,et al.  Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. , 2014, The New England journal of medicine.

[35]  T. Mesana,et al.  Ischemic mitral regurgitation: current trends and treatment , 2013, Current opinion in cardiology.

[36]  Jennifer Taylor,et al.  ESC/EACTS Guidelines on the management of valvular heart disease. , 2012, European heart journal.

[37]  Bing Li,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[38]  A. Weill,et al.  French national health insurance information system and the permanent beneficiaries sample. , 2010, Revue d'epidemiologie et de sante publique.

[39]  Grégoire Rey,et al.  Ecological association between a deprivation index and mortality in France over the period 1997 – 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death , 2009, BMC public health.

[40]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[41]  Philippe Ravaud,et al.  A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.

[42]  M. Enriquez-Sarano,et al.  Natural History of Asymptomatic Mitral Valve Prolapse in the Community , 2002, Circulation.

[43]  M. Enriquez-Sarano,et al.  Chapter 76 – Mitral Regurgitation , 2009 .